Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Other financing activities: 2015-2022

Historic Other financing activities for Syndax Pharmaceuticals (SNDX) over the last 6 years, with Mar 2022 value amounting to $92,000.

  • Syndax Pharmaceuticals' Other financing activities rose 16.46% to $92,000 in Q1 2022 from the same period last year, while for Mar 2022 it was $13,000, marking a year-over-year decrease of 18.75%. This contributed to the annual value of $1,000 for FY2020, which is 99.45% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Other financing activities stood at $92,000 for Q1 2022, which was up 138.02% from -$242,000 recorded in Q4 2021.
  • Over the past 5 years, Syndax Pharmaceuticals' Other financing activities peaked at $207,000 during Q4 2018, and registered a low of -$242,000 during Q4 2020.
  • Its 3-year average for Other financing activities is $10,333, with a median of $79,000 in 2021.
  • As far as peak fluctuations go, Syndax Pharmaceuticals' Other financing activities surged by 3,500.00% in 2018, and later tumbled by 524.56% in 2020.
  • Over the past 5 years, Syndax Pharmaceuticals' Other financing activities (Quarterly) stood at $207,000 in 2018, then tumbled by 72.46% to $57,000 in 2019, then slumped by 524.56% to -$242,000 in 2020, then remained steady at -$242,000 in 2021, then climbed by 16.46% to $92,000 in 2022.
  • Its Other financing activities stands at $92,000 for Q1 2022, versus -$242,000 for Q4 2021 and $99,000 for Q3 2021.